239 related articles for article (PubMed ID: 20110631)
21. Combining traditional agents and biologics for the treatment of psoriasis.
Cather JC; Menter A
Semin Cutan Med Surg; 2005 Mar; 24(1):37-45. PubMed ID: 15900797
[TBL] [Abstract][Full Text] [Related]
22. Biologic therapies in psoriasis: a new therapeutic approach.
Gisondi P; Girolomoni G
Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
[TBL] [Abstract][Full Text] [Related]
23. Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report.
Cirone KD; Lovegrove FE
SAGE Open Med Case Rep; 2023; 11():2050313X231160937. PubMed ID: 36968989
[TBL] [Abstract][Full Text] [Related]
24. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
25. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
[TBL] [Abstract][Full Text] [Related]
26. Generalized pustular psoriasis of Zambusch: case report of successful disease control with cyclosporine and etanercept.
Vine K; Votava HJ; Smith BL
Cutis; 2012 Sep; 90(3):132-6. PubMed ID: 23094312
[TBL] [Abstract][Full Text] [Related]
27. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
28. Acrodermatitis continua of hallopeau successfully treated with adalimumab.
Sopkovich JA; Anetakis Poulos G; Wong HK
J Clin Aesthet Dermatol; 2012 Feb; 5(2):60-2. PubMed ID: 22468174
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
30. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Rallis E; Verros CD
Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
[No Abstract] [Full Text] [Related]
31. Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature.
Galluzzo M; D'Adamio S; Teoli M; Bianchi L; Talamonti M
Dermatol Ther; 2019 May; 32(3):e12899. PubMed ID: 30969010
[TBL] [Abstract][Full Text] [Related]
32. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
33. Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series.
Bhutani T; Koo J
J Dermatolog Treat; 2011 Apr; 22(2):75-8. PubMed ID: 20524874
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
[TBL] [Abstract][Full Text] [Related]
35. [Suppurative acrodermatitis continua of Hallopeau. A differential diagnosis of paronychia].
Mooser G; Pillekamp H; Peter RU
Dtsch Med Wochenschr; 1998 Mar; 123(13):386-90. PubMed ID: 9556694
[TBL] [Abstract][Full Text] [Related]
36. Lack of efficacy of etanercept in acrodermatitis continua of Hallopeau.
Adişen E; Oztaş M; Gürer MA
Int J Dermatol; 2007 Nov; 46(11):1205-7. PubMed ID: 17988345
[No Abstract] [Full Text] [Related]
37. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
38. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
39. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
Strober BE; Poulin Y; Kerdel FA; Langley RG; Gu Y; Gupta SR; Okun MM; Papp KA
J Am Acad Dermatol; 2011 Apr; 64(4):671-81. PubMed ID: 21414495
[TBL] [Abstract][Full Text] [Related]
40. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
